search
Front

BiolineRX share jumps on buy offer for US partner

19 Jul, 2010 18:08
שלח תגובה במיילYael Gruntman

Cypress Bioscience is completing clinical trials and regulatory procedures for Bioline's schizophrenia treatment.

BiolineRX Ltd. (TASE:BLRX) saw its share price jump today after New York asset manager Ramius LLC bid $4 share for Cypress Bioscience Inc. (Nasdaq: CYPB), which has an out-license to complete clinical trials and regulatory procedures for one of the Israeli company's drugs. At one point, Bioline's share price was up 8% on its opening price but it fell back to close up 3.2% on the day at NIS 3.51.

Ramius, which already holds 9.9% of San Diego drug producer Cypress Bioscience, proposed buying the rest of the company for $4 per share in cash, 60% above its Friday close of $2.50 per share, and 74% above its share price in mid-June when Cypress Bioscience bought the license for Bioline's schizophrenia treatment BL-1020.

In addition to its buy offer, Ramius said that it would consider a purchase structure that would enable the company's management to continue developing Bioline's BL-1020 and finance the phase II clinical trial either independently or with a third party as the funding body. Such a purchasing structutre could reach a 50% holding in BL-1020.

Published by Globes, Israel business news - www.globes-online.com - on July 19, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

Bezalel Smotrich and Amir Yaron credit: Knesset Spokesperson and Tali Bogdanovsky Retail chains, credit card cos could soon act as banks

Israel's financial regulators have proposed that supermarket chains, credit card companies and investment houses will be able to accept deposits and offer credit.

Nvidia VP Ali Kani credit: Nvidia Nvidia intensifies efforts to compete with Mobileye

"Globes" talks to Nvidia VP and automotive team head Ali Kani about the chipmaker's autonomous vehicle activities and assesses the threat to Mobileye.

Elbit Systems rocket launcher credit: Elbit Systems Elbit Systems wins $130m European rocket order

The order is for the supply of rockets for Elbit's Precise and Universal Launching System (PULS), which has an effective range of up to 300 kilometers.

Fitch ratings agency credit: Shutterstock Fitch reaffirms Israel's A rating with negative outlook

The ratings agency said, "The negative outlook reflects rising public debt, domestic political and governance challenges and uncertain prospects for the conflict in Gaza."

Miri Regev and Yitzhak Rochberger credit: Yediot Ahronot/ Reuven Kapuchinsky and Amit Shabi Ramat Hasharon wants railway station for the Mossad

Ramat Hasharon is pushing for a station in Glilot neat the Mossad headquarters, even though a new station is also planned for Glilot South, 1.6 kilometers away.

Fencing goes up Petah Tikva's Segula neighborhood credit: NTA Work on Metro to begin in Petah Tikva

The first work on the Tel Aviv Metropolitan underground railways system will begin on the M2 line depot in Petah Tikva.

Highcon chairperson Shlomo Nimrodi credit: PR Packaging tech co Highcon winding down

The company, which numbers Benny Landa and JVP among its investors, is laying off most of its workforce, having lost 99.9% of its value since its flotation.

Big banks CEOs credit: Oren Dai, Jonthan Bloom and Israel Hadari Israeli banks unveil NIS 3b customer benefits package

The benefits over two years meet the target set by the Bank of Israel to ease the burden for customers, while the banks are reporting record profits.

Record public company profits credit: Tali Bogdanovsky Profits peak, but reckoning awaits

In what may seem a paradox, profits grew in almost every sector on the Tel Aviv Stock Exchange last year, but the boom was largely fueled by government spending.

Tel Aviv Stock Exchange credit: PR Volumes peak on Tel Aviv Stock Exchange

Greater optimism in Israel and a shift away from US markets have brought trading volumes in Tel Aviv to a historical high, but will the trend be sustained?

Ishay Davidi credit: Cadya Levy FIMI CEO: Foreign investors flocking back to Israel

Ishay Davidi told the Globes "Going Long on Israel" Conference that investors who pulled out of Israel after October 7 have begun returning in large numbers.

Tel Aviv Stock Exchange credit: Shutterstock Tel Aviv stocks: Rebound or long slide?

Statistics show a two-thirds chance of high returns after a steep one-day fall. Yields on Israel government bonds are rising sharply.

Tamar rig credit: PR Sovereign Wealth Fund earned handsome returns in 2024

Israel's Sovereign Wealth Fund, known as the Citizens' Fund, had assets worth about $2 billion at the end of 2024, the Ministry of Finance reports.

Bank of Israel credit: Shutterstock/Alon Adika Bank of Israel slams gov't fiscal policy

Governor Prof. Amir Yaron wrote in the annual report that the government's measures are not enough to ensure a sustained decline in debt-to-GDP ratio.

Minimum wage credit: Tali Bogdanovsky Minimum wage in Israel to rise next week

The monthly minimum wage in Israel will be revised upwards by 6%.

Moody's, Benjamin Netanyahu, Bezalel Smotrich, credit: Shutter stock, Government Spokesperson, Tali Bogdanovsky Moody's: Political risks weigh on Israel's rating

"Israel's sovereign credit profile reflects very high political risks that have weakened economic and fiscal strength."

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018